Recent studies have focused on the overlap of glucagon-like peptide-1|GIP|glucagon receptor stimulant therapies and dopamine signaling. While GLP agonists are increasingly employed for treating type 2 T2DM, their potential consequences on reinforcement circuits, specifically mediated by dopaminergic systems, are attracting significant attention. Th